Dania Therapeutics ApS: Financial statements 2025
CVR: 42523925
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Dania Therapeutics ApS (CVR 42523925) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -3,390,139 and a net result of DKK -5,039,754 compared with DKK -9,556,855 the year before. Equity in the 2025 report amounted to DKK -15,413,086. The company had 1 employee in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -3,390,139
- Profit/Loss
- DKK -5,039,754
- Equity
- DKK -15,413,086
- Total Assets
- DKK 3,502,316
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 0 | -3.4M | -5M | -15.4M | 1 |
| 2024 | 0 | -8.8M | -9.6M | -10.4M | 1 |
| 2023 | 0 | -9.2M | -8.7M | -1.2M | 1 |
Official annual report
How creditworthy is Dania Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Dania Therapeutics ApS has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -9,556,855.
About Dania Therapeutics ApS
Dania Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Karin Absalonsen. The board consists of Karin Absalonsen (chair), Kristian Helin and Michael Manchuan Li. The company is owned by Kristian Helin, Hannibal Innovation ApS and Vernalis (R&D) Limited. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -3,390,139 and a net result of DKK -5,039,754 compared with DKK -9,556,855 the year before. Equity in the 2025 report amounted to DKK -15,413,086.